Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure

Nath, M. et al. (2022) Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.2540) (PMID:35570197) (Early Online Publication)

[img] Text
267942.pdf - Accepted Version
Restricted to Repository staff only until 15 May 2023.

1MB
[img] Text
267942Suppl.pdf - Supplemental Material
Restricted to Repository staff only until 15 May 2023.

2MB
[img] Other (Supplementary Tables)
267942SupplTables.xlsx - Supplemental Material
Restricted to Repository staff only until 15 May 2023.

224kB

Abstract

Aims Chronic Heart Failure (CHF) is a systemic syndrome with a poor prognosis and a need for novel therapies. We investigated whether whole-blood transcriptomic profiling can provide new mechanistic insights into cardiovascular (CV) mortality in CHF. Methods and Results Transcriptome profiles were generated at baseline from 944 CHF patients from the BIOSTAT-CHF Study - of whom 626 survived and 318 died from a CV cause during a follow-up of 21 months. Multivariable analysis, including adjustment for cell count, identified 1,153 genes (6.5%) that were differentially expressed between those that survived or died and strongly related to a validated clinical risk score for adverse prognosis. The differentially expressed genes mainly belonged to 5 non-redundant pathways: Adaptive immune response, proteasome-mediated ubiquitin-dependent protein catabolic process, T-cell co-stimulation, positive regulation of T-cell proliferation and erythrocyte development. These five pathways were selectively related (RV coefficients >0.20) with seven circulating protein biomarkers of CV mortality (FGF23, sST2, adrenomedullin, hepcidin, pentraxin-3, WFDC2 and IL-6) revealing an intricate relationship between immune and iron homeostasis. The pattern of survival-associated gene expression matched with 29 perturbagen-induced transcriptome signatures in the iLINCS drug-repurposing database, identifying drugs, approved for other clinical indications, that were able to reverse in vitro the molecular changes associated with adverse prognosis in CHF. Conclusion Systematic modeling of the whole blood protein-coding transcriptome defined molecular pathways that provide a link between clinical risk factors and adverse cardiovascular prognosis in CHF, identifying both established and new potential therapeutic targets.

Item Type:Articles
Status:Early Online Publication
Refereed:Yes
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Nath, M., Romaine, S. P.R., Koekemoer, A., Hamby, S., Webb, T. R., Nelson, C. P., Castellanos-Uribe, M., Papakonstantinou, M., Anker, S. D., Lang, C. C., Metra, M., Zannad, F., Filippatos, G., van Veldhuisen, D. J., Cleland, J. G., Ng, L. L., May, S. T., Marelli-Berg, F., Voors, A. A., Timmons, J. A., and Samani, N. J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:European Journal of Heart Failure
Publisher:Wiley
ISSN:1388-9842
ISSN (Online):1879-0844
Published Online:15 May 2022
Copyright Holders:Copyright © 2022 European Society of Cardiology
First Published:First published in European Journal of Heart Failure 2022
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record